The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the space that’s about to go clinical!”.
Broad Media Coverage of the launch of Sound Bioventures Fund I
Evolving to the next phase of viral therapy development
UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and readjusting in both the lab and the boardroom. Successful growth requires adaptation, and Theolytics CEO/Co-Founder Charlotte Casebourne Stock knows all ab ...
Earthquakes, investing in drugs, and how to be decent in Venture Capital.
Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series. The discussion included Johan’s journey from scientist to seasoned life science investor, the importance of risk management, why a portfolio approach is key when you invest in ...
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Stockholm, Sweden and Washington D.C., USA – 17 April 2024 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic vi ...
Beyond fundraising: how do venture capitals build early-stage biotechs?
It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant role in building the company with its founders. To better understand the dynamic between biotech startups and VCs, we talked to Johan […]